LC Sciences and DNAVision form Strategic Marketing Alliance
News May 07, 2008
LC Sciences announced that it has entered into a strategic marketing alliance with DNAVision to increase accessibility to its custom microRNA profiling service and enhance both its customer and technical service to researchers in Europe.
LC Sciences’ microRNA profiling service is powered by µParaflo® microfluidic technology and makes use of flexible custom microarrays for expression profiling as well as discovery of small RNAs and validation of predicted microRNAs.
“We are very excited about this alliance with DNAVision, clearly one of the quality leaders of microarray and other molecular biology services,” says Chris Hebel, Director of Business Development at LC Sciences.
“Although we are currently serving customers globally from our headquarters in the U.S., we felt is was important to extend our reach and provide local service to areas where there is a concentration of microRNA research occurring, like Europe. DNAVision has extensive microarray and microRNA expertise in-house and can provide not only ordering convenience but also real technical guidance to researchers in this rapidly advancing field,” Hebel continued.
“We are delighted to combine our quality gene expression services with the technology developed by LC Sciences.” said Jean-Pol Detiffe, CEO of DNAVision. “This agreement is a new evidence that DNAVision is becoming the technical partner of choice for microRNA expression profiling, using all the latest technologies available on the market” added Michäel Herman, DNAVision, Business Development Director.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.